The Challenge of Preventive Treatment of HDAs in Europe

"We're very happy that it didn't make it to the European market and then we get an extension of the time to think about how we want to handle this," he says. "It's going to be a really harsh discussion in the public domain when it becomes clear that this is just not bearable for the healthcare system no one has this kind of money yeah I think that'll be the first one comes"